Protox To Present Interim Prostate Cancer Data at AUA Conference
VANCOUVER, British Columbia, Sept. 6, 2007 /CNW/ - Protox
Therapeutics Inc. (TSX-V:PRX) today announced that interim
data from the recently completed Phase 1 clinical study
testing PRX302 in patients with locally recurrent prostate cancer
following radiation failure will be presented at the American
Urological Association ("AUA") South Central Section Annual
Meeting. The conference will take place at the Broadmoor Hotel
in Colarado Springs,
Scott Coffield, M.D., Principal Investigator from the lead site at Scott and White Memorial Hospital, will present the data on Friday, September 7, 2007. The presentation, entitled "Interim Results of a Phase 1 Clinical Study for the Transperineal Intraprostatic Administration of PRX302 (PSA-PAH1) in Patients with Locally Recurrent Prostate Cancer" indicates that PRX302 is safe and well tolerated in patients and that it shows encouraging signs of therapeutic activity.
PRX302 is rationally designed to kill prostate cancer and hyperplastic cells that over-produce the enzyme prostate specific antigen (PSA). Patient enrollment has been completed for this Phase 1 study and top-line results were released in July indicating that PRX302 is safe and well tolerated and that a maximum tolerated dose was not reached in the study while encouraging signs of therapeutic activity were observed. Plans are currently underway to commence a Phase 2 study before the end of the year.
Protox Therapeutics is a leader in advancing novel, targeted protein toxin therapeutics for the treatment of cancer and other proliferative diseases. The company is actively developing two distinct but complementary platforms, INxin(TM) and PORxin(TM), and currently has four clinical programs in development. A Phase 2a clinical trial into the use of PRX321 (INxin) for the treatment of primary brain cancer has been completed and the drug has received Fast Track Designation and Orphan Drug Status from the US FDA. In addition, a Phase 1 trial has been completed for PRX321 to treat patients with renal cell carcinoma and non-small cell lung cancer. Patient enrollment has been completed for a Phase 1 clinical trial into the use of PRX302 (PORxin) for the treatment of localized prostate cancer. A Phase 1 clinical study of PRX302 for the treatment of benign prostatic hyperplasia (enlarged prostate) is ongoing.
NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS RELEASE. THE TSX VENTURE EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Certain statements included in this press release may be
considered forward-looking. Such statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results, performance or achievements to be materially
different from those implied by such statements, and
therefore these statements should not be read as guarantees of
future performance or results. All forward-looking statements
are based on Protox' current beliefs as well as assumptions
made by and information currently available to Protox and
relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory
developments, market acceptance and future commitments.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including
the risks and uncertainties identified by Protox in its
public securities filings; actual events may differ
materially from current expectations. Protox disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future
events or otherwise.
For further information: James Beesley, Director, Investor Relations, Protox Therapeutics, (604) 688-0199, email@example.com; Michael Moore, Investor Relations, Equicom Group, (416) 815-0700 x 241, firstname.lastname@example.org
Posted: September 2007